Oncology Oracle Questions

Question 1

In the BTC 01 Trial the most common grade 3 adverse reaction was_________

Answer 1

Anemia 13%

Question 2

In the BTC 01 Trial the second most common grade 3 AE was _______

Answer 2

Diarrhea 9%

Question 3

In the BTC 01 Trial the third most common grade 3 AE was ________

Answer 3

Increased ALT/AST 5%

Question 4

In the BTC 01 Trial the fourth most common grade 4 AE was_______

Answer 4

Fatigue 4%

Question 5

In BTC 01 the most common treatment emergent lab abnormality was_____

Answer 5

Low Hb 14%

Question 6

BTC 01 the second most common treatment emergent lab abnormality was____

Answer 6

elevated ALT 8% and elevated AST 10%

Question 7

BTC 01 the third most common treatment emergent lab abnormality was_______

Answer 7

Low sodium 10%

Question 8

BTC 01 the fourth most common treatment emergent lab abnormality was _______

Answer 8

Low Lymphocytes 8%

Question 9

In BTC 01 treatment emergent AE’s led to dose reductions in______ due to_______

Answer 9

4% patients, diarrhea (3%) nausea (1%) and decreased weight (1%).

Question 10

In BTC 01 the discontinuation rate due to AE’s was _________

Answer 10

2.5%

Question 11

BTC 01 AE’s leading to permanent discontinuation were______

Answer 11

Decreased ejection fraction 1.3% and Pneumonitis 1.3%

Question 12

In BTC 01 Serious AE’s occurred in_____

Answer 12

13.8% and those that occurred in >2% included diarrhea (3%) and Fatigue (3%)

Question 13

With respect to the primary endpoint the ORR by ICR was________

Answer 13

41.3%

Question 14

In BTC 01 Did any patients experience a CR?

Answer 14

Yes, 2

Question 15

Median Dor in BTC 01 was ____

Answer 15

14.9 months

Question 16

In BTC 01 and Among those who were IHC 3+ and ISH amplified the cORR was____ and median DoR was____

Answer 16

52% and 15 months

Question 17

In BTC 01and Among those who were IHC 2+ and ISH amplified the cORR was ____ and the median DoR was ______

Answer 17

6% and Not Evaluable

Question 18

In BTC 01 and by AJCC how many were stage 4?

Answer 18

(71) 89%

Question 19

BNTC 01 how many had greater than 1 prior line of therapy?

Answer 19

41%

Question 20

BTC 01 How many had prior Gemcitabine therapy

Answer 20

(80) 100%

Question 21

More than ___________people are diagnosed each year with BTC

Answer 21

12,000

Question 22

BTC is most often ____________ at diagnosis

Answer 22

Asymptomatic

Question 23

At diagnosis patients may experience symptoms of ________, ________, _______, ________, _________.

Answer 23

Fatigue, Weight Loss, nausea, fever or jaundice.

Question 24

Initial diagnostic tests focus on _______, ______ and _________

Answer 24

Imaging, Blood Tests, Biopsy

Question 25

An estimated _____ to ______% of patients with BTC are diagnosed when the disease is in the advanced or metastatic state

Answer 25

60-85%

Question 26

PD-L1 expression of >1% is observed in up to _____% of BTC tumors

Answer 26

70%

Question 27

Most patients with BTC remain on their First line therapy the longest, an average of _____ months

Answer 27

3.8 months

Question 28

HER2 therapies are not prescribed in the first line setting T/F?

Answer 28

T

Question 29

According to the NCCN __________ is the preferred second line therapy for BTC

Answer 29

Folfox

Question 30

MSI-H (dMMR) observed in _______ of BTC's

Answer 30

1-3%

Question 31

HER2 overexpression or gene amplification; observed in _______% of CCA’s and ______% of GBC’s.

Answer 31

5-20%, 15-30%

Question 32

9-15% of iCCA’s harbor _______

Answer 32

FGFR2 Gene fusions or rearrangements.

Question 33

1-5% of BTC’s harbor _______

Answer 33

BRAF V600E

Question 34

10-20% of iCCA’s harbor ______

Answer 34

IDH1

Question 35

Select 1L therapies that are category 1

Answer 35

Durvalumab or Pembrolizumab +Gem/Cis, and GEM/CIS by itself.

Question 36

Durvalumab indicated with GEM/CIS for _______

Answer 36

locally advanced and metastatic BTC

Question 37

Pembrolizumab indicated with GEM/CIS for _______

Answer 37

locally advanced, UNRESECTABLE or Metastatic BTC

Question 38

Durvalumab is a _______antibody

Answer 38

PD-L1 blocking

Question 39

Pembrolizumab is a _______ antibody

Answer 39

PD-1 blocking

Question 40

Gemcitabine (Category 2A) is a ________

Answer 40

Nucleoside Metabolic Inhibitor

Question 41

FOLFOX regimen contains _________

Answer 41

Folinic Acid - Chemotherapy Modulating Agent Fluorouracil Oxaliplatin

Question 42

Keytruda Monotherapy can be given first line for ______

Answer 42

MSI-H (dMMR) Category 2A

Question 43

Dosing for Durvalumab for patients >30 Kg in weight is __________

Answer 43

1500 mg +G/C every 3 weeks up to 8 cycles followed by 1500 mg every 4 weeks

Question 44

Dosing for Durvalumab for patients <30 Kg in weight is __________

Answer 44

20 mg/kg +G/C every 3 weeks up to 8 cycles followed by 20mg/kg every 4 weeks

Question 45

Durva G/C OS______, PFS______, investigator ORR______,DoR_______

Answer 45

12.8mos, 7.2 mos, 27%, 6.4 mos

Question 46

Pembro G/C OS_____, PFS _____, BICR assessed ORR_____, DoR______

Answer 46

12.7mos, 6.5 mos,29%, 8.3 mos

Question 47

Second line cat 2A Therapies include:

Answer 47

Futibatinib, Pemigatinib, Trastuzumab+Pertuzumab, Trastuzumab+Tucatinib, T-Dxd, Zanidatamab

Question 48

Futibatinib is an inhibitor of_____, and given _____mg orally 1/day

Answer 48

FGFR 1,2,3,4, 20mg

Question 49

Pemigatinib is an inhibitor of ______, and given _____mg orally 1/day

Answer 49

FGFR1,2,3, 13.5mg

Question 50

Enhertu approved in 2024 for _______

Answer 50

HER2 Positive Solid Tumors

Question 51

Enhertu dosed at______

Answer 51

5.4mg/kg

Question 52

Other choices of 2L therapy include:

Answer 52

Trastuzumab monotherapy or Trastuzumab plus pembrolizumab